Maze Therapeutics, Inc. (MAZE) CEO Coloma sells 34,501 shares via trusts
Rhea-AI Filing Summary
Maze Therapeutics, Inc. Chief Executive Officer Jason V. Coloma reported indirect sales totaling 34,501 shares of common stock on August 3, 2026. Shares held by The Coloma 2021 Irrevocable Trust and the Coloma Family Trust, for which Coloma and his spouse are co‑trustees, were sold in four non‑derivative transactions at weighted average prices of $26.7145, $27.0940, $26.7140, and $27.0853 per share, executed pursuant to a Rule 10b5‑1 trading plan adopted on February 6, 2026.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Net Seller: 34,501 shares
Net Sell
4 txns
Insider
Coloma Jason V
Role
Chief Executive Officer
Sold
34,501 shs ($922K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2, F3 | 2,439 | $26.7145 | $65K |
| Sale | Common Stock F1, F4, F3 | 154 | $27.094 | $4K |
| Sale | Common Stock F1, F5, F6 | 30,304 | $26.714 | $810K |
| Sale | Common Stock F1, F7, F6 | 1,604 | $27.0853 | $43K |
Holdings After Transaction:
Common Stock — 20,744 shares (Indirect, The Coloma 2021 Irrevocable Trust);
Common Stock — 255,263 shares (Indirect, Coloma Family Trust)
Footnotes (7)
- F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
- F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.01 to $26.97 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 4, 5, and 7 of this Form 4.
- F3. These securities are directly held by The Coloma 2021 Irrevocable Trust, for which the reporting person and his spouse serve as co-trustees.
- F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.04 to $27.16 per share, inclusive.
- F5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.005 to $26.985 per share, inclusive.
- F6. These securities are directly held by the Coloma Family Trust, for which the reporting person and his spouse serve as co-trustees.
- F7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.04 to $27.19 per share, inclusive.
Key Figures
Total shares sold: 34501 shares
Shares sold by The Coloma 2021 Irrevocable Trust: 2439 shares
Additional shares sold by The Coloma 2021 Irrevocable Trust: 154 shares
+3 more
6 metrics
Total shares sold
34501 shares
Aggregate common stock sold indirectly on August 3, 2026
Shares sold by The Coloma 2021 Irrevocable Trust
2439 shares
Non-derivative sale of common stock at $26.7145 per share
Additional shares sold by The Coloma 2021 Irrevocable Trust
154 shares
Non-derivative sale of common stock at $27.0940 per share
Shares sold by Coloma Family Trust
30304 shares
Non-derivative sale of common stock at $26.7140 per share
Additional shares sold by Coloma Family Trust
1604 shares
Non-derivative sale of common stock at $27.0853 per share
Price range for first trust sale
$26.01–$26.97 per share
Range of individual trade prices underlying weighted average in footnote F2
Key Terms
Rule 10b5-1 trading plan, weighted average price, Irrevocable Trust, co-trustees
4 terms
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The reported price in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Irrevocable Trust other
"These securities are directly held by The Coloma 2021 Irrevocable Trust"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
co-trustees other
"for which the reporting person and his spouse serve as co-trustees."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider stock transactions did Maze Therapeutics (MAZE) report for Jason V. Coloma?
Maze Therapeutics CEO Jason V. Coloma reported indirect sales totaling 34,501 common shares on August 3, 2026. Four non-derivative transactions involved 2,439 and 154 shares from The Coloma 2021 Irrevocable Trust and 30,304 and 1,604 shares from the Coloma Family Trust.
Were Jason V. Coloma’s MAZE stock sales made under a Rule 10b5-1 plan?
Yes. The reported transactions were effected under a Rule 10b5-1 trading plan adopted on February 6, 2026. A plan-based structure means trades follow pre-set instructions rather than ad hoc decisions about timing.